Anika

Anika Therapeutics, Inc. is a global leader in joint preservation and early intervention orthopedic care, founded in 1992. The company develops and manufactures minimally invasive products aimed at managing osteoarthritis pain and repairing damaged tissues and tendons. Anika's core expertise lies in its proprietary hyaluronic acid (HA) technology, which supports a diverse range of products, including viscosupplement injections, regenerative scaffolds, and bone-preserving joint technologies. Notable offerings include Orthovisc, Tactoset Injectable Bone Substitute, the Integrity Implant System, and Hyalofast. Anika has expanded its portfolio through strategic acquisitions, enhancing its capabilities in sports medicine and orthopedic implants. The company collaborates closely with orthopedic surgeons, sports medicine specialists, and healthcare providers to create solutions that improve patient outcomes and quality of life. Anika's mission is to lead in joint preservation by delivering advancements in orthopedic care. The company values quality, integrity, innovation, teamwork, and accountability, fostering a culture dedicated to restoring active living worldwide.

• Employees290
• Founded1992
• Annual Revenue$137444000